parallel randomized trial
S002920
Type 2 diabetes (adults)S002920
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Insulin glargine Insulin glargine plus insulin aspart (control) | preprandial insulin aspart three times daily; lifestyle: standard | 63 | 63 | |
| A2 | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated IDegLira plus insulin aspart (observation) | preprandial insulin aspart three times daily; lifestyle: standard | 63 | 63 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Insulin glargine A1 | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated A2 |
|---|---|---|---|
| age | mean (years) | 58.48 | 55.81 |
| bmi | median (kg/m2) | 28.57 | 27.99 |
| bmi | q1 (kg/m2) | 25.95 | 25.97 |
| bmi | q3 (kg/m2) | 30.32 | 30.48 |
| diabetes duration | median (years) | 4 | 4 |
| diabetes duration | q1 (years) | 3 | 3 |
| diabetes duration | q3 (years) | 6 | 5 |
| female | n | 30 | 27 |
| hba1c | median (percent) | 10.2 | 10.1 |
| hba1c | q1 (percent) | 8.67 | 8.9 |
| hba1c | q3 (percent) | 11.42 | 11.2 |
Results
4 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Level 2 or 3 hypoglycemia (participants) (4 lines; O04)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 9 / 63 | not stated; randomized; R0005989:Table 3 | ||||
| A1 | events | 28 / 63 | not stated; randomized; R0005989:Table 3 | ||||
| A2 | events | 3 / 63 | not stated; randomized; R0005989:Table 3 | ||||
| A2 | events | 19 / 63 | not stated; randomized; R0005989:Table 3 |